stockportfolio.pro
Stocks / AMBA vs DBD
AMBA vs DBD
Ambarella, Inc. and Diebold Nixdorf, Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Technology.
| Ambarella, Inc. (AMBA) | Diebold Nixdorf, Incorporated (DBD) | |
|---|---|---|
| Market cap | $2.8B | $2.8B |
| Revenue (latest FY) | $390.70M | $3.81B |
| Net income (latest FY) | $-75.86M | $94.60M |
| Revenue growth (5y CAGR) | 11.9% | -0.5% |
| Net margin | -19.4% | 2.5% |
| Return on equity | -12.8% | 8.6% |
| P/E ratio | — | 27.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 1 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMBA — free Open DBD — freeFrequently asked questions
Which is bigger, AMBA or DBD?
Diebold Nixdorf, Incorporated is larger by market capitalization — $2.8B versus $2.8B.
Which grows faster, AMBA or DBD?
Over the last five fiscal years, Ambarella, Inc. grew revenue faster — 11.9%/yr versus -0.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.